STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer

STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer
Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients receiving a dose of 2.9 mg/kg or higher responded to this investigational antibody-drug conjugate, and nearly half (44%) had responses lasting at least 16 weeks, results showed. These findings were presented by Wendel Naumann, MD, the trial's principal investigator, in a virtual poster, “Phase 1 Dose-Escalation Study of STRO-002, An Anti-Folate Receptor Alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Platinum-Resistant/Refractory Epithelial Ovarian Cancer (OC)” at the 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society (IGCS) on Sept. 10. STRO-002, an antibody-drug conjugate, is made of an antibody that specifically binds to folate receptor alpha (FRα), a protein found at high levels in most types of ovarian cancer. The binding is designed to trigger the release of a toxic compound that kills tumor cells, while leaving healthy cells unharmed. The open-label Phase 1 trial (NCT03748186) is assessing the safety, tolerability, and preliminary efficacy of STRO-002 in women with ovarian cancer (including fallopian and primary peritoneal cancer) and endometrial cancer who received prior platinum-based chemotherapy. In the study's first part, women were given increasing doses of STRO-002 — ranging from 0.5 mg/kg to 6.4 mg/kg — to determine the therapy’s optimal dose. This is being followed by a dose expansion part, in which participants will be treated with the recommended dose. As of Aug. 31, a total of 39 heavily pre-treated women (median of five prior chemothe
Subscribe or to access all post and page content.